Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics

BACKGROUND: Although hydrochlorothiazide (HCTZ) is a well‐established first‐line antihypertensive in the United States, <50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahin, Mohamed H., Gong, Yan, Frye, Reginald F., Rotroff, Daniel M., Beitelshees, Amber L., Baillie, Rebecca A., Chapman, Arlene B., Gums, John G., Turner, Stephen T., Boerwinkle, Eric, Motsinger‐Reif, Alison, Fiehn, Oliver, Cooper‐DeHoff, Rhonda M., Han, Xianlin, Kaddurah‐Daouk, Rima, Johnson, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778957/
https://www.ncbi.nlm.nih.gov/pubmed/29288159
http://dx.doi.org/10.1161/JAHA.117.006656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778957/
https://www.ncbi.nlm.nih.gov/pubmed/29288159
http://dx.doi.org/10.1161/JAHA.117.006656

Ejemplares similares